Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery

Lantern Pharma (NASDAQ: LTRN) announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), delivering a real-time, web-based molecular intelligence engine that enables researchers to generate comprehensive developability profiles for small molecules from a single SMILES input. The enhanced platform leverages Lantern’s RADR AI technology to provide rapid, high-dimensional analysis across physicochemical properties, drug-likeness, structural architecture and topological mapping, with benchmark-validated performance and accessibility designed to streamline drug discovery workflows and broaden access to advanced computational tools.

The expansion of predictBBB into an LQM represents a significant advancement in computational drug discovery. By allowing researchers to input a single SMILES string—a notation for chemical structures—and receive a full developability profile, the platform aims to reduce the time and cost associated with early-stage drug development. This is particularly important for small molecules, which often face challenges related to blood-brain barrier penetration, solubility, and toxicity. The integration with Lantern’s RADR AI platform ensures that the analysis is not only rapid but also highly accurate, as it is benchmarked against validated datasets.

This announcement is important because it democratizes access to advanced AI-driven drug discovery tools. Traditionally, such computational analyses required significant expertise and resources, limiting their use to large pharmaceutical companies or specialized research institutions. By offering this as a web-based service, Lantern Pharma is making it accessible to a broader range of researchers, including those in academia and smaller biotech firms. This could accelerate the discovery of new therapies, particularly for diseases that require drugs to cross the blood-brain barrier, such as neurological disorders and brain cancers.

Lantern Pharma is a clinical-stage precision oncology company that uses AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company’s pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. Additionally, Lantern’s withZeta.ai platform, a multi-agentic AI co-scientist, is now commercially available as a subscription-based research platform, representing a new revenue stream for the company.

The expansion of predictBBB into an LQM could have significant implications for the pharmaceutical industry. By enabling rapid screening of molecular properties, it may help identify promising drug candidates earlier in the development process, reducing the risk of late-stage failures. This aligns with broader industry trends toward using AI to improve drug discovery efficiency. For investors, this development signals Lantern Pharma’s commitment to leveraging its AI capabilities not only for its own pipeline but also as a service to the wider research community, potentially opening up new revenue opportunities.

For more information, visit the full press release at https://ibn.fm/XqWld.